Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Vor Bio announced post hoc 48-week Phase 3 data from collaborator RemeGen's China trial of telitacicept in generalized myasthenia gravis, presented at the 2026 AANEM annual meeting. More than 94% of participants achieved at least a 5-point MG-ADL improvement at Week 48, and 42% of telitacicept-treated participants reached minimal symptom expression at some point over 48 weeks, up from 23.7% through 24 weeks. Durability was the highlight: 86.7% of MSE events were sustained at the next monthly assessment, and participants spent 83-85% of remaining follow-up in MSE, with no new safety signals observed.
Key figures
- Drug Name
- telitacicept
- Phase Of Trial
- Phase 3
- Phase3 randomized
- 114
- Mse baseline mg adl 6 10
- 51%
- Mse baseline mg adl ge11
- 21%
- Pct achieving mse first 24wk
- 23.7%
- Max mg adl improvement week48
- 13
- Pct followup in mse crossover
- 85%
- Pct achieving mse any time 48wk
- 42%
- Pct followup in mse telitacicept
- 83%
- Pct mg adl 5pt improvement week48
- 94%
- Pct mse sustained next assessment
- 86.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.